Interleukin-12 as an adjuvant for mucosal vaccination against pneumococcal disease.

Trial Profile

Interleukin-12 as an adjuvant for mucosal vaccination against pneumococcal disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 May 2017

At a glance

  • Drugs Interleukin-12 (Primary)
  • Indications Pneumococcal infections
  • Focus Therapeutic Use
  • Acronyms Mucosal IL-12 Pneumovac
  • Most Recent Events

    • 01 Oct 2011 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 07 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top